title: Recent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting.
abstract: Nausea and vomiting remain among the most feared side effects of chemotherapy for cancer patients. Significant progress has been made in the last 15 years in developing more effective and better-tolerated measures to minimize chemotherapy-induced nausea and vomiting (CINV). During the 1990s, the selective 5-hydroxytryptamine receptor antagonists were first introduced for the treatment of CINV, and resulted in more effective and better tolerated treatment of CINV. Despite recent progress, however, a significant number of patients still develop CINV, particularly during the 2-5-day period (delayed emesis) following chemotherapy. There is evidence that this may be an underappreciated problem on the part of some caregivers. Recently, two new antiemetics, aprepitant, the first member of the neurokinin-1 antagonists, and palonosetron, a second-generation 5-hydroxytryptamine receptor antagonist, received regulatory approval in the U.S. Both represent useful additions to the therapeutic armamentarium for the management of CINV.
authors: Department of Pharmacology, S.D.M.College of Medical Sciences and Hospital, Sattur, Dharwad, Karnataka, India.
authors: Prasan R
authors: PR
authors: Bhandari
keywords: Antiemetics; cancer; chemotherapy; nausea; vomiting
references: Cancer. 2004 Dec 1;101(11):2701-8
references: 15517574
references: Br J Clin Pharmacol. 1998 Jun;45(6):525-38
references: 9663807
references: Support Care Cancer. 1997 Jan;5(1):31-7
references: 9010987
references: Arch Dis Child. 2004 Sep;89(9):877-80
references: 15321871
references: Ann Pharmacother. 2003 Sep;37(9):1276-86
references: 12921512
references: Drugs. 2009;69(13):1853-78
references: 19719336
references: Eur J Pharmacol. 2001 Oct 5;428(2):215-20
references: 11675038
references: J Support Oncol. 2005 Sep-Oct;3(5):369-74
references: 16218261
references: Lancet. 1982 Mar 20;1(8273):658-9
references: 6121969
references: Drugs. 1985 Aug;30(2):127-44
references: 2863127
references: J Clin Oncol. 2003 Nov 15;21(22):4112-9
references: 14559886
references: Nat Clin Pract Oncol. 2005 Apr;2(4):196-201
references: 16264934
references: Clin Pharmacokinet. 2005;44(6):637-47
references: 15910011
references: Eur J Pharmacol. 1993 Nov 30;250(1):R5-6
references: 8119305
references: Oncology (Williston Park). 2005 Apr;19(5):637-45
references: 15945344
references: Ann Oncol. 2004 Feb;15(2):330-7
references: 14760130
references: Support Care Cancer. 1998 May;6(3):204-14
references: 9629871
references: J Clin Oncol. 1997 Jan;15(1):103-9
references: 8996130
references: N Engl J Med. 2008 Jun 5;358(23):2482-94
references: 18525044
references: Cancer. 1996 Mar 1;77(5):941-8
references: 8608488
references: Clin Pharmacol Ther. 2003 Aug;74(2):150-6
references: 12891225
references: Br J Pharmacol. 1995 Dec;116(8):3158-63
references: 8719790
references: Ann Oncol. 2003 Oct;14(10):1570-7
references: 14504060
references: Oncology (Williston Park). 2007 Jul;21(8):946-53; discussion 954, 959, 962 passim
references: 17715696
references: J Clin Oncol. 1996 Aug;14(8):2242-9
references: 8708713
references: Drugs. 2009;69(5):515-33
references: 19368415
references: Physiol Rev. 2003 Jul;83(3):1017-66
references: 12843414
references: Cancer. 2003 Jun 15;97(12):3090-8
references: 12784346
references: Ann Pharmacother. 2005 Jan;39(1):77-85
references: 15562136
references: Cancer. 1989 Sep 1;64(5):1117-22
references: 2667749
references: Br J Cancer. 1997;76(8):1055-61
references: 9376266
references: Pharmacol Rev. 2002 Jun;54(2):161-202
references: 12037135
references: J Clin Oncol. 1997 Jan;15(1):116-23
references: 8996132
references: Prog Neuropsychopharmacol Biol Psychiatry. 2002 May;26(4):721-30
references: 12188105
references: Support Care Cancer. 2005 Apr;13(4):219-27
references: 15538640
references: Eur J Cancer. 1992;28(2-3):450-7
references: 1534250
references: Gen Pharmacol. 1995 Sep;26(5):911-44
references: 7557266
references: Cancer Nurs. 2005 Jul-Aug;28(4):249-55
references: 16046885
references: Clin Pharmacol Ther. 2003 Jul;74(1):17-24
references: 12844131
references: Br J Pharmacol. 2004 May;142(1):9-19
references: 15100161
references: Behav Brain Res. 1984 Mar;11(3):277-81
references: 6721920
references: Cancer. 2003 Dec 1;98(11):2473-82
references: 14635083
references: J Support Oncol. 2004 Jul-Aug;2(4):305-14; discussion 314-6
references: 15357514
references: Eur J Pharmacol. 1993 Nov 2;249(1):R3-4
references: 7506663
references: J Clin Oncol. 1995 May;13(5):1242-8
references: 7738628
references: Oncologist. 1999;4(3):191-6
references: 10394587
references: Ther Clin Risk Manag. 2009 Apr;5(2):375-84
references: 19536319
references: Indian Pediatr. 2010 Feb;47(2):149-55
references: 20228428